Scott

@TheIdeaFarm @MebFaber Where is GVAL positioned here?

🌎 Global Stock Market Valuations 🌎 theideafarm.com/quarterly-glob…

@JonahLupton Will charge so much in other countries and if they will pay if they do? Or will it be like pharma where the price is way less for volume. No idea how this would affect margins. Have to think they make a bundle charging 80k/case, basically getting most of hospital profit.

Looks like we have confirmation that $TMDX will continue expanding in Europe, now doing training in Belgium. Investors are underestimating how well $TMDX will do with international growth/expansion over the next 3-5 years. By the end of 2027, I expect $TMDX to be in 6+ countries in Europe as well as announce expansion plans for Asia-Pacific which would include Australia at some point.

Long time partner, mentor and friend @EdLinEmory received a massive and well deserved Ponsky Master educator award @SAGES_Updates today! Super proud. Many old trainees came to celebrate him.

@JonahLupton I’m with you owning shares but comparison to ISRG isn’t really a good one as they have a massive and growing addressable market. Organs to donate are very finite and they have a lot of share already. Adding new organs is still small compared to all of MIS procedures

I have no idea where $TMDX goes in the short term (also don't care because I know it goes much higher in the longer term)... with that said it's possible the stock finally fills the May 2025 gap-up at $98.50 which is also the VWAP from the October 2024 gap-down. It almost closed the gap-up in July 2025 but missed by $0.40 -- obviously I have no idea if that gap fills or not, just pointing it out. If that gap does fill, it means $TMDX would be trading at approx 4.2 NTM ev/revs which is kind of ridiculous considering where I believe revs and eps are going over the next 3-5 years (more below). If that gap does fill, the $TMDX multiple would be the lowest it's been since the January 2025 lows and we all know how great of a buying opportunity that was and how much shareholders have been rewarded in the past when they're buying this stock below 5x NTM ev/revs. Since the 2019 IPO, $TMDX has traded below 5x NTM ev/revs on 5 different occasions (March 2020, November 2020, February 2022, October 2023 and January 2025)... you can see how well the stock has performed every single time off those lows... always up triple digits within the next 12 months. Keep in mind that $SWAV got acquired a couple years ago by $JNJ at 13x NTM ev/revs (with similar fundamentals) and $ISRG currently trades at 14x NTM ev/revs (with much lower growth rates).... the $TMDX multiple/valuation under 5x NTM rev/revs is starting to look silly since I think revenues grow at a 25% CAGR through 2030 while earnings grow at a 35% CAGR through 2030. I would have to assume larger medtech companies (ie $JNJ, $MDT and $BSX) are sniffing around $TMDX at these prices... although I doubt the $TMDX management team would accept anything below $200 per share. NFA. DYOR. *I own $TMDX personally and so does @FirstWaveFund

@GauchoRico Interesting mix of deltas on your calls. What is the overarching strategy with them? Are you levering up when you think price is low? That wouldn’t explain your APP trade tho

Long-dated call options (21.3% of portfolio): APP (9.9%): Jun'27 $600Cs, Jan'28 $390Cs, $460Cs, and $510Cs AXON (4.2%): Jan'28 $440Cs MELI (1.0): Jan'28 $1720Cs NVDA (6.2%): Dec'27 $170Cs, Jan'28 $185Cs and $190Cs 3/6

27Feb’26 Growth Stock Portfolio Allocations $NVDA 23.3% $APP 20.6% $AXON 18.4% $MELI 15.3% $IREN 10.2% $RDDT 9.5% $ALAB 8.6% cash -5.8% YTD -19.13% YTD hi +7.8% (13Jan) YTD lo -25.1% (5Feb) CAGR +31.2% (9.16 yrs; since 1/1/17) changes this week 👇 1/6

@BourbonCap @grok how has this portfolio done since post if equal weighted

11 Stocks to Buy and Hold for the Next Decade 1. Amazon $AMZN Amazon remains a global powerhouse across cloud, logistics, and retail, and is expected to maintain this leadership into the next decade through aggressive expansion in India, Latin America, and the Middle East. AWS holds 32% of the global cloud market, and by 2035 it could remain the world’s largest cloud platform, generating $300B+ in annual revenue while expanding its AI-as-a-service offerings. Generative AI demand is now a multibillion-dollar business, growing at triple-digit YoY rates, with demand outpacing supply. Amazon Pharmacy continues to scale rapidly, with 50% YoY growth, capitalizing on the momentum in digital health. With over 250M Prime members worldwide, Amazon enjoys unmatched customer loyalty and competitive advantage and expects to double Prime membership by 2032. By 2035, ads are projected to become one of Amazon’s largest cash flow drivers, rivaling AWS. This will enable the company to continue reinvesting heavily in logistics, e-commerce, AI, and emerging technologies. Project Kuiper has successfully launched its third satellite and already secured enterprise and government customers, positioning Amazon to compete in satellite broadband. Thanks to its vast ecosystem, Amazon is expected to become the first company to surpass $1 trillion in annual revenue by 2029, underscoring its unmatched scale and ability to monetize across multiple industries.

@grok @JackJ3596 @CitronResearch @ grok what are their short calls in last 12 months

Citron is Short $SNDK — They Don't Ring a Bell at the Top We don't need Anthropic to announce they're making NAND. Samsung is already the 800-pound gorilla, and they've been running this playbook for 30 years. While TV pundits pound the table herding retail into cattle cars, Western Digital, the long time investor, sold a significant portion of its holdings days ago, 25% lower. Ask yourself why. Because they know the cycle is approaching a peak, and they're not waiting for the bell. The market is pricing SanDisk like it's $NVDA. There's one problem: NVIDIA has a moat. SanDisk sells a commodity. We've seen this movie before 2008, 2012, 2018. It's never different this time. Memory is a cycle, and cycles peak. Samsung has a 30-year history of choosing market share over margins. They wait for pure-plays like SanDisk to get comfortable at 50% gross margins, then flip the switch. But this time it's worse. Every $SNDK bull should read attached article Samsung just told the world they won't sell anything under 50% margins and they're moving their best chips into the same premium SSD market SanDisk calls home. They're not just the capacity gorilla anymore. They're going after SanDisk's best customers with cheaper, newer technology. And the only thing keeping supply tight right now? Samsung's temporary yield problems in another product line. That bottleneck has an expiration date. With double the capacity of the 2018 peak waiting in the wings, this "shortage" is a supply mirage that can vanish in a single earnings call. Hockey shout-out: Shorting $SNDK is skating to where the puck is going. By the time the cycle normalizes, this stock will already be much lower. technetbooks.com/2026/02/samsun…

@drowsyinvestor Impossible to get home and not get 2-3comments about what was done wrong and takes 3x longer

Me nailing 63% of a grocery shopping list my wife wrote for me. x.com/NBA/status/202…

@dee_bosa I thought you were talking about being a doctor for a while….

Freight forwarding is an industry that still largely runs on faxes, phone calls, PDFs emailed back and forth... ie. it hasn't fundamentally changed in decades. It may not be obvious but its the kind of thing AI eats first (tons of coordination, low digitization, high friction)

@saxena_puru The website performance table has a table ending in June still. Do you guys not update it? I wish the comments had more happy subs

Gen AI market projected to ~3x by 2029* AI stocks are currently deeply oversold and pullbacks during secular uptrends are good opportunities. Our portfolio is positioned in some of the leading AI businesses alphatarget.com *Source: S&P Global Market Intelligence

@Clippy2025 @AllKindsWeather Yeah was in person for that one too. Pretty close

I can only remember two other points in time where it legit looked like the players didn’t want to be there. 2017 @ MO, 2021 @ SC. That’s it. Accusing a team of quitting is the last line of defense in terms of analyzing a losing product, but can anybody really say they haven’t?

@EricKnauerMD @eastpak My Jandlort from HS still in play!

On the right my made in USA Eastpak high school back pack. Check the prolene I used to repair the zipper in med school. Trust me, it spent a lot of time on my back stuffed with text books. On the left my Doctors Day backpack. Strap ripped off today. @eastpak #MadeInUSA

@OMGhanemMD @MayoClinic @MayoClinicSurg @MayoSurgery @IBCClub1 They were just waiting for you to officially be professor before delivering this heavy talk

Honored to deliver an invited lecture at the IBC Congress-University of Oxford. While there’s no definitive formula for “What Makes an Excellent Surgeon?”, the rich history, heritage, & current practices at @MayoClinic served as an insightful framework to approach this topic

@JRogrow @TravisHoium Look into highlands or lake glenville area in north Ga! Those are our favorites coming out of Atlanta. Lake Chatuge is very pretty also

@TravisHoium Yep, that is the exact view I'm looking for. Thanks. Travis.

I want to visit a beautiful mountain town in North Carolina, Kentucky, Tennessee, Virginia, or even North Georgia this fall. Most importantly, I want stunning views of the mountains...so a town that sits up high with views of the mountains below or in the distance. Also looking for great downtown area with good coffee shops and restaurants. Where should I visit? Thanks so much.🙏

@drowsyinvestor Will this be on Apple Podcasts anytime soon? I forget to check Spotify for these

JUST RELEASED: "Episode 3: Investing Strategies, Monthly Reviews, and Hoards of Finance Bros" of Shooting the Bull With Drowsy and Bear. We chat some extreme valuations, our investing strategies, old high flyer names, and Drowsy brings out the $100s. creators.spotify.com/pod/profile/dr…

@ElliotServaisMD @EricKnauerMD @rbarbosa91 @CPark_MD @VNikolian @ericpaulimd @TomVargheseJr @EzraTeitelbaum @cutitoutPODCAS1 @RScott571 @FilipinoSurgeon If everyone comes in at 715, and a preop nurse has 3-4 patients, 2-3 cases are going to be late to start. It isn’t a big ask for each group to arrive at a time that the others can complete their tasks to start on time. What was the fine? Can’t book first case for while?

@EricKnauerMD @rbarbosa91 @CPark_MD @VNikolian @ericpaulimd @sdavis81 @TomVargheseJr @EzraTeitelbaum @cutitoutPODCAS1 @RScott571 @FilipinoSurgeon “But Officer, other people were speeding too, so why do I have to follow the rules?” You show up on-time and lead by example because you are an adult and a professional

For first case starts how long before the case are you required to be in preop. (Case time being wheels in). Leave a comment @rbarbosa91 @CPark_MD @VNikolian @ericpaulimd @sdavis81 @TomVargheseJr @EzraTeitelbaum @cutitoutPODCAS1 @RScott571 @FilipinoSurgeon

@drowsyinvestor Would $AXON qualify in this category now? Pretty massive valuation ratios all around

Another “valuation” and “opportunity cost” lesson with Drowsy. Finally about even on my $MNDY position. Bought most shares in 2021. 🧐

@OMGhanemMD @rbarbosa91 @EricKnauerMD @EdLinEmory @AnkitPatelMD I want to suggest alternatives for procedural docs that they resonate with but everything I think of is an OR access metric, not really a clinic one

@rbarbosa91 @sdavis81 @EricKnauerMD @EdLinEmory @AnkitPatelMD We have triage system

Can any surgeons comment on metrics used in surgical clinics to incentivize process improvement and improved access? We found common metrics like “new patients seen in 10 days%” and “new patient mix” may ring true in medical clinics primarily and dont inspire for surgeons

@OMGhanemMD @rbarbosa91 @EricKnauerMD @EdLinEmory @AnkitPatelMD But they want us to see everything an everyone. Today or tomorrow. Surgeons need the records but patients want expediency. The surgeons don’t resonate with metrics that may work in medical clinics and so don’t want to strive for them. They want the OR booked.